Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis

International Journal of Radiation Oncology Biology Physics

Volumn 45, Issue 2, 1999, Pages 491-499

  McLendon, Roger E ^a   Archer, Gary E ^a   Larsen, Roy H ^a   Akabani, Gamal ^a   Bigner, Darell D ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Astatine 211; Glioma; Monoclonal antibodies; Radioimmunotherapy; Radiotoxicity

Indexed keywords

ASTATINE 211; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CONTROLLED STUDY; DRUG TOXICITY; FEMALE; GLIOMA; LETHAL DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RADIOISOTOPE THERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTATINE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOTOXINS; MALE; MICE; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; SEX FACTORS;

EID: 0032867794     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00206-0     Document Type: Article

References (36)

1. 211At]-astatinated endoradiotherapeutic drug: Part IV - Late radiation effects. Int J Radiat Oncol Biol Phys 1998;40:1177-1183.
2. 90Y . Int J Radiat Oncol Biol. 10:1984;341-348.
3. 211At in a murine intraperitoneal tumor model. Gyn Oncol. 57:1995;9-15.
4. 211At-labeled chimeric monoclonal antibodies on human glioma and melanoma cells in vitro. Radiat Res. 149:1998;155-162.
5. 211At]astatobenzylguanidine on human neuroblastoma cells. Cancer Res. 54:1994;5414-5419.
6. 211At]astato-2′-deoxyuridine, an α-particle emitting endoradiotherapeutic agent undergoing DNA incorporation. Cancer Res. 56:1996;1204-1209.
7. Zalutsky M.R., McLendon R.E., Garg P.K., et al. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res. 54:1994;4719-4725.
8. Zalutsky M.R., Stabin M., Larsen R.H., et al. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an α-particle emitting immunoconjugate. Nucl Med Biol. 24:1997;255-262.
9. 211At-methylene blue for targeted radiotherapy of disseminated melanoma Microscopic analysis of tumour versus normal tissue damage . Eur J Cancer. 32A:1996;1986-1994.
10. 211At]-astatinated endoradiotherapeutic drug Part II. Therapeutic results for transplanted adenocarcinoma of the rectum in mice . Int J Radiat Oncol Biol Phys. 30:1994;115-124.
11. 211At]methylene blue for targeted radiotherapy of human melanoma xenografts Dose fractionation in the treatment of cutaneous tumours . Eur J Cancer. 32A:1996;1240-1247.
12. Roeske J.C., Chen G.T.Y. A dosimetry model for intracavitary radioimmunotherapy of cystic brain tumors. Antibody Immunoconj Radiopharm. 4:1991;637-647.
13. 2 - A preliminary report. J Neuro-Oncol. 24:1995;109-122.
14. Bigner D.D., Brown M.T., Friedman A.H., et al. Iodine-131-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas Phase I trial results . J Clin Oncol. 16:1998;2202-2212.
15. Bourdon M.A., Wikstrand C.J., Furthmayr H., et al. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 43:1983;2796-2805.
16. He X., Archer G.E., Wikstrand C.J. Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin. J Neuroimmunol. 52:1994;127-137.
17. Zalutsky M.R., Archer G.E., Garg P.K., et al. Chimeric anti-tenascin antibody 81C6 Increased tumor localization compared with its murine parent . Nucl Med Biol. 23:1996;449-458.
18. 211At reaction. Appl Radiat Isotop. 47:1996;135-143.
19. 2 fragments with the alpha particle emitting nuclide astatine-211 Preservation of immunoreactivity and in vivo localizing capacity . Proc Natl Acad Sci USA. 86:1989;7149-7153.
20. Goodman D.G., Boorman G.A., Strandberg J.D. Selection and use of the B6C3F1 mouse and F344 rat in long-term bioassays for carcinogenicity. Milman H.A., Weisburg E.K. Handbook of carcinogen testing. 1985;282-325 Noyes Publications, Park Ridge, NJ.
21. Skipper H.E., Schmidt L.H. A manual of quantitative drug evaluation in experimental tumor systems. Cancer Chemother Rep. 17:1962;1-143.
22. 1 and BALB/c (nu/nu) mice A long-term survival study with histologic analysis . Int J Radiat Oncol Biol Phys. 35:1996;69-80.
23. 211At-markierten humanserumalbumin-mikrosphären - erste klinische erfahrungen. NucCompact. 21:1990;124-127.
24. Cobb L.M., Harrison A., Butler S.A. Toxicity of astatine-211 in the mouse. Human Toxicol. 7:1998;529-534.
25. Cobb L.M., Butler S.A., Harrison A. The effect of the α-particle emitter Astatine-211 in the mouse at the minimum toxic dose. Hum Exp Toxicol. 9:1990;289-293.
26. Hamilton J.G., Asling C.W., Garrison W.M., et al. The accumulation, metabolism and biological effects of astatine in rats and monkeys. Univ Calif Pub Pharmacol. 2:1953;283-344.
27. 2 fragment. Cancer Res. 50:1990;3514-3520.
28. Zalutsky M.R., Stabin M.G., Larsen R.H., et al. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an α-particle-emitting immunoconjugate. Nucl Med Biol. 24:1997;255-261.
29. Sung S., van Osdol W.W. Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding. J Nucl Med. 36:1995;867-876.
30. Sgouros G. Bone marrow dosimetry for radioimmunotherapy Theoretical considerations . J Nucl Med. 34:1993;689-694.
31. Lim S.M., DeNardo G.M., DeNardo S.A., et al. Prediction of mylotoxicity using radiation doses to marrow from body, blood, and marrow sources. J Nucl Med. 38:1997;1374-1378.
32. Akabani G., Zalutsky M.R. Microdosimetry of astatine-211 using histological images Application to bone marrow . Radiat Res. 148:1997;599-607.
33. Stinchcomb T.G., Roeske J.C. Analytical microdosimetry for radioimmunotherapeutic alpha emitters. Med Phys. 19:1992;1385-1393.
34. Durbin P.W., Asling C.W., Johnston M.E., et al. The induction of tumors in the rat by astatine-211. Radiat Res. 9:1958;378-397.
35. Yokoro K., Kunii A., Furth J., et al. Tumor induction with astatine-211 in rats Characterization of pituitary tumors . Cancer Res. 24:1964;683-688.
36. 1) mice. J Natl Cancer Inst. 63:1979;849-854.